Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer

The triple-negative breast cancer (TNBC) is a very aggressive tumor type often occurring in young women and is associated with a bad prognosis for the patients. TNBC lacks established targets for breast cancer therapy, such as the estrogen receptor (ER), progesterone receptor (PR) and the human epid...

Descripción completa

Detalles Bibliográficos
Autores principales: Huber, Michaela C., Falkenberg, Natalie, Hauck, Stefanie M., Priller, Markus, Braselmann, Herbert, Feuchtinger, Annette, Walch, Axel, Schmitt, Manfred, Aubele, Michaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190079/
https://www.ncbi.nlm.nih.gov/pubmed/27286449
http://dx.doi.org/10.18632/oncotarget.9853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190079/
https://www.ncbi.nlm.nih.gov/pubmed/27286449
http://dx.doi.org/10.18632/oncotarget.9853

Ejemplares similares